Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERI-LONG
2024-517713-33-00Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome and myalgic encephalomyelitis (ME) comparing Vericiguat with Placebo (2 arms). Primary endpoint: Intra-patient change in SF-36 physical functioning (SF-36-PF) from baseline to week 10. Started Nov 2024; status: completed.
02
Drugs
vericiguat
03
Conditions
post-COVID syndromemyalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on 2024-517713-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517713-33-00.